FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | |
|--------------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden | |
| hours per response: | 0.5 |
| | |

| | Check this box if no longer subject to Section 16. Form 4 |
|----|---|
| ıı | or Form 5 obligations may continue. See Instruction 1(b) |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | | or Section | on 30(n) of the | Investmen | it Comp | any Act of | 1940 | | | | | | | | | |
|---|---|--|------------|---|--|--|--------------------------|--|---------|--|--|-------------------|--|---|---|--|--|---|---|--|
| 1. Name and Address of Reporting Person* <u>Carino Tanisha</u> | | | | | 2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS, INC. [ALXN] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | | |
| | | | | | | | | | | | | | l x | | au er (aive title b | nelow) | | | ecify below) | |
| (Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 02/28/2020 | | | | | | | | | EVP & CCAO | | | | | | |
| (Street) BOSTON MA 02210 | | | | If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | |
| (City) | State) | (Zip |)) | | | | | | | | | | | | | | | | | |
| | | | 7 | Table I - | Non-Der | ivative Se | curities A | cquired, | Dispo | osed of | , or Bene | ficially Ov | ned | | | | | | | |
| 1. Title of Security (Instr. 3) | | | | 2. Transact Date | Execu | Execution Date, ar) if any | | 3. Transaction 4. Secur Code (Instr. 8) 3, 4 and | | ities Acquired (A) or Disposed Of (D 5) | | ed Of (D) (Instr. | Beneficially Owned F Reported Transaction | | ollowing Direct (D) or Indirect (I) | | | 7. Nature of Indirect Beneficial | | |
| | | | (Month/Day | | ode V Amount | | | (A) or (D) | | Price | Ownership (Instr. 4) | | | | | | | | | |
| Common Stock, par value \$.0001 per share | | | | | 02/28/2 | /28/2020 | | Α | | 9,5 | 9,520 ⁽¹⁾ A | | \$0 | | 18,297 | | | D | | |
| | | | | Table I | | | rities Acq , warrants | | | | | | ed | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | | 4. Transac (Instr. 8) | ction Code | 5. Number of Derivative Securities Acquired (A) Disposed of (D) (Instr. 3, and 5) | | 6. Date Exercisable Expiration Date (Month/Day/Year) | | | and 7. Title and Amount of Securities Derivative Security (Instr. 3 and 4 | | | Deri | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following | | O. Ownership Form: Direct D) or Indirect I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisa | | xpiration ate | Title | | Amount or Number of Sh | ares | | Reported Transaction(s) (Instr. 4) | | | | |

Explanation of Responses:

1. Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.

Remarks:

/s/ Douglas Barry, Attorney-in-Fact for Tanisha Carino 03/03/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

* If the form is filed by more than one reporting person, see Is U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Known all by these presents, that the undersigned hereby constitutes and appoints William Wheeler and Douglas Barry, each signing singly, the undersigned's true

- (1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Alexion Pharmaceuticals, Inc. (the "Company"), Forms
- (2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4, 5 (or any 5
- (3) Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best:

 The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necess.

 This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5 (or any successor forms) and any

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of October, 2019.

/s/ Tanisha Carino (signature)

Tanisha Carino